NCT05498480View on ClinicalTrials.gov

Study of Relatlimab in Combination With Nivolumab in Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

January 18, 2024

Study Completion Date

January 18, 2024

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

Relatlimab

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (1)

201315

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05498480 - Study of Relatlimab in Combination With Nivolumab in Chinese Participants | Biotech Hunter | Biotech Hunter